Emtricitabine
- Generic Name
- Emtricitabine
- Brand Names
- Atripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10FN3O3S
- CAS Number
- 143491-57-0
- Unique Ingredient Identifier
- G70B4ETF4S
- Background
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.
Emtricitabine was granted FDA approval on 2 July 2003.
- Indication
Emtricitabine is indicated in combination with other medications for the treatment of HIV-1 infections; treatment of HIV-1 infections in pediatric patients 25-35kg, treatment of HIV-1 infections in adult patients ≥35kg, for pre exposure prophylaxis of HIV-1 in adolescent and adult patients excluding those who have receptive vaginal sex; treatment of HIV-1 infections in pediatric and adult patients ≥17kg, pre exposure prophylaxis in adolescents and adults ≥35kg; treatment of HIV-1 in patients ≥12 years and ≥35kg; treatment of HIV-1 in patients weighing ≥35kg; treatment of HIV-1 in patients weighing ≥25kg; and treatment of HIV-1 in patients weighing ≥40kg.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Pre-Exposure Prophylaxis (PrEP)
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
- Conditions
- Human Immunodeficiency Virus (HIV)-1 Infection
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT00380159
- Locations
- 🇪🇸
Clinical Trial Site, Madrid, Spain
Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 566
- Registration Number
- NCT00346567
- Locations
- 🇹🇿
Bombo Regional Hospital, Tanga, Tanzania
Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)
- Conditions
- HIV InfectionPregnancy
- First Posted Date
- 2006-06-07
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Target Recruit Count
- 72
- Registration Number
- NCT00334256
- Locations
- 🇨🇮
Centre de Prise en Charge et de Formation ACONDA, Abidjan, Côte D'Ivoire
🇰🇭Calmette Hospital, Phnom Penh, Cambodia
🇿🇦PHRU, Soweto, South Africa
SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2008-07-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 220
- Registration Number
- NCT00323544
- Locations
- 🇬🇧
Gilead Sciences, Cambridge, United Kingdom
Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 106
- Registration Number
- NCT00307489
A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-25
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 357
- Registration Number
- NCT00192634
- Locations
- 🇦🇺
QLD Health - AIDS Medical Unit, Brisbane, Queensland, Australia
🇦🇺John Hunter Hospital, Newcastle, New South Wales, Australia
🇦🇺The Centre Clinic, Melbourne, Victoria, Australia
Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)
- Conditions
- HIV Infection
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-07-03
- Lead Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Target Recruit Count
- 40
- Registration Number
- NCT00158457
- Locations
- 🇸🇳
Centre de Traitement Ambulatoire, CHU de Fann, Dakar, Senegal
🇸🇳Service des Maladies Infectieuses, CHU de Fann, Dakar, Senegal
Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection
- Conditions
- HIV InfectionsHepatitis B
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2007-04-24
- Lead Sponsor
- International Antiviral Therapy Evaluation Center
- Target Recruit Count
- 24
- Registration Number
- NCT00127959
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, NH, Netherlands
Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)
- Conditions
- HIV InfectionsTuberculosis
- First Posted Date
- 2005-06-24
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Target Recruit Count
- 70
- Registration Number
- NCT00115609
- Locations
- 🇫🇷
Service des maladies Infectieuses et tropicales Hopital Necker-Enfants Malades, Paris, France
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
- Conditions
- HIV Infections
- Interventions
- Drug: FTC/TDFDrug: FTC/TDF/EFV
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 517
- Registration Number
- NCT00112047
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸AIDS Healthcare Foundation Research, Beverly Hills, California, United States
🇺🇸Capital Medical Associates, P.C., Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.